Business Context and Reporting Period
This Form 8-K was filed by CalciMedica, Inc. on March 29, 2024. The company is incorporated in Delaware and trades on The Nasdaq Capital Market under the symbol "CALC". The report details a corporate action regarding an equity financing program.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The only financial data disclosed relates to the company's At-The-Market (ATM) offering program:
- Previous Maximum Offering Price: $4,700,000
- New Maximum Offering Price: $17,068,386
- Shares Sold to Date: Aggregate sales price of $279,771.74
Material Changes
On March 29, 2024, CalciMedica increased the maximum aggregate offering price of shares issuable under its ATM Offering Agreement with H.C. Wainwright & Co. The limit was raised from $4,700,000 to $17,068,386. A prospectus supplement was filed to cover the increased amount.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure of the equity offering. The document notes the filing of a legal opinion regarding the legality of the shares issuable under the updated agreement.
Investor Verification Checklist
- Verify the current share price and market capitalization to assess the potential dilution impact of the new $17,068,386 offering limit.
- Review the full Prospectus Supplement to understand the specific terms and conditions of the ATM offering.
- Check recent 10-Q or 10-K filings for the company's current cash position and burn rate to determine the necessity of this capital raise.
- Confirm the total number of shares authorized for issuance under the updated agreement.